Kinase-deficient CMVpp65 triggers a CMVpp65 specific T-cell immune response in HLA-A*0201. Kb transgenic mice after DNA immunization

Scandinavian Journal of Immunology

Volumn 55, Issue 6, 2002, Pages 592-598

  Gallez Hawkins, G ^a   Lomeli, N A ^a   Li, X L ^a   Yao, Z Q ^a   La Rosa, C ^a   Diamond, D J ^a   Zaia, J A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ASPARAGINE; CMVPP65 VACCINE; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; HLA A2 ANTIGEN; LEUKOCYTE ANTIGEN; LYSINE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; TRANSGENIC MOUSE; VIRUS MUTANT;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PHOSPHOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINIA VIRUS; VIRAL MATRIX PROTEINS;

EID: 0036096703     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2002.01099.x     Document Type: Article

References (59)

1. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age
2. Congenital cytomegalovirus infection
3. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients
4. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
5. Cytomegalovirus infection in the pregnant mother, fetus, and newborn infant
6. Preclinical evaluation of an ALVAC (canarypox) - Human cytomegalovirus glycoprotein B vaccine candidate
7. Cytomegalovirus vaccine
8. Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus
9. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein
10. Cytomegalovirus antigenemia assay: Identification of the viral antigen as the lower matrix protein pp65
11. T and B cell responses to cytomegalovirus antigens in healthy blood donors and bone marrow transplant recipients
12. A 64,000 dalton matrix protein of human cytomegalovirus induces in vitro immune responses similar to those of whole viral antigen
13. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response
14. + T cell responses against a cytomegalovirus antigen
15. + T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants
16. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus
17. + virus-specific cytotoxic T lymphocytes
18. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells
19. Induction of human cytomegalovirus (HCMV) -glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization
20. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones
21. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses
22. Human cytomegalovirus virion-associated protein with kinase activity
23. Properties of a human cytomegalovirus-induced protein kinase
24. Genomic location of a human cytomegalovirus protein with protein kinase activity (PK68)
25. Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting
26. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL
27. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
28. Structural analysis of a 64-kDa major structural protein of human cytomegalovirus (Towne): Identification of a phosphorylation site and comparison to pp65 of HCMV (AD 169)
29. Enzyme activity dot blots for assaying protein kinases
30. Expression of proteins in mammalian cells using vaccinia virus vectors
31. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex
32. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: Dependence on HLA class II restricted T (H) response
33. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLAA2 and a variant of HLA-A28
34. Genetic polymorphism within HLA-A*02: Significant allelic variation revealed in different populations
35. Genetic vaccines
36. DNA vaccines: Vector design, delivery, and antigen presentation
37. Polo-like kinase 1 as a target for human cytomegalovirus pp65 lower matrix protein
38. Infrequent occurrence of natural mutations in the pp65 (495-503): Epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates
39. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome
40. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice
41. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression
42. Molecular interactions of coreceptor CD8 and MHC class I. The molecular basis for functional coordination with the T-cell receptor
43. Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules
44. Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase
45. Designing peptide vaccines to broaden recognition and enhance potency
46. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1
47. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope
48. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design
49. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: Implications for vaccine design
50. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8 (+) cytotoxic T-cell epitopes
51. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants
52. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M 1 protein
53. Transgenic mice expressing human HLA and CD8 molecules generate HLA-restricted measles virus cytotoxic T lymphocytes of the same specificity as humans with natural measles virus infection
54. Generation and characterization of malaria-specific human CD8 (+) lymphocyte clones: Effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentationby liver cells
55. H-2 class I knockout, HLA-A2.1-transgenic mice: A versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies
56. Peptide vaccines against hepatitis B virus: From animal model to human studies
57. Maintenance of CD8 (+) T-cell memory following infection with recombinant sindbis and vaccinia viruses
58. A recombinant human papillomavirus (HPV) type 16, L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles
59. HLA-A2.1-restricted education and cytolytic activity of CD8 (+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice